WO2017011773A3 - Codon-optimized nucleic acids encoding antibodies - Google Patents

Codon-optimized nucleic acids encoding antibodies Download PDF

Info

Publication number
WO2017011773A3
WO2017011773A3 PCT/US2016/042568 US2016042568W WO2017011773A3 WO 2017011773 A3 WO2017011773 A3 WO 2017011773A3 US 2016042568 W US2016042568 W US 2016042568W WO 2017011773 A3 WO2017011773 A3 WO 2017011773A3
Authority
WO
WIPO (PCT)
Prior art keywords
codon
methods
nucleic acids
optimized nucleic
acids encoding
Prior art date
Application number
PCT/US2016/042568
Other languages
French (fr)
Other versions
WO2017011773A2 (en
Inventor
Joseph Beene BOLEN
Stephen Hoge
Iain Mcfadyen
Original Assignee
Modernatx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx, Inc. filed Critical Modernatx, Inc.
Publication of WO2017011773A2 publication Critical patent/WO2017011773A2/en
Publication of WO2017011773A3 publication Critical patent/WO2017011773A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure discloses compositions comprising codon-optimized nucleotide sequences, in particular mRNAs, that encode antibodies and functional fragments thereof (e.g., antigen-binding fragments or Fc fragments that can be used in fusion proteins). These optimized nucleic acid sequences can be used to expressing therapeutic antibodies in vivo. Also provided are methods of manufacturing the disclosed codon-optimized nucleotide sequences, methods of generating therapeutic antibodies in a subject in need thereof by administering a polynucleotide comprising a codon-optimized nucleotide sequence, and methods for treating and/preventing a disease or condition in a subject using the disclosed compositions and methods.
PCT/US2016/042568 2015-07-15 2016-07-15 Codon-optimized nucleic acids encoding antibodies WO2017011773A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562193018P 2015-07-15 2015-07-15
US62/193,018 2015-07-15

Publications (2)

Publication Number Publication Date
WO2017011773A2 WO2017011773A2 (en) 2017-01-19
WO2017011773A3 true WO2017011773A3 (en) 2017-03-23

Family

ID=57757614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/042568 WO2017011773A2 (en) 2015-07-15 2016-07-15 Codon-optimized nucleic acids encoding antibodies

Country Status (1)

Country Link
WO (1) WO2017011773A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170362627A1 (en) * 2014-11-10 2017-12-21 Modernatx, Inc. Multiparametric nucleic acid optimization
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
SI3718565T1 (en) 2015-10-22 2022-08-31 Modernatx, Inc. Respiratory virus vaccines
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. Influenza vaccine
TW202313678A (en) 2017-01-20 2023-04-01 法商賽諾菲公司 Anti-tgf-beta antibodies and their use
AR110755A1 (en) 2017-01-20 2019-05-02 Genzyme Corp BONE DIRECTED ANTIBODIES
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
MA52262A (en) 2017-03-15 2020-02-19 Modernatx Inc BROAD SPECTRUM VACCINE AGAINST THE INFLUENZA VIRUS
US20200030432A1 (en) 2017-03-17 2020-01-30 Modernatx, Inc. Zoonotic disease rna vaccines
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
UY37758A (en) * 2017-06-12 2019-01-31 Novartis Ag METHOD OF MANUFACTURING OF BIESPECTIFIC ANTIBODIES, BISPECTIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
CN111212905A (en) 2017-08-18 2020-05-29 摩登纳特斯有限公司 RNA polymerase variants
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. Methods for hplc analysis
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
BR112020007405A2 (en) * 2017-10-18 2020-12-08 Regenxbio Inc. TOTALLY HUMAN HUMAN MODIFIED ANTIBODY THERAPEUTIC PRODUCTS
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
WO2022212191A1 (en) * 2021-04-01 2022-10-06 Modernatx, Inc. Mucosal expression of antibody structures and isotypes by mrna
WO2023030635A1 (en) * 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
WO2023154678A1 (en) * 2022-02-08 2023-08-17 Amgen Inc. Codon-optimized nucleic acids encoding ocrelizumab

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258420A1 (en) * 2005-08-01 2009-10-15 Herman Van Vlijmen Altered polypeptides, immunoconjugates thereof, and methods related thereto
US20140186382A1 (en) * 2002-12-23 2014-07-03 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186382A1 (en) * 2002-12-23 2014-07-03 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US20090258420A1 (en) * 2005-08-01 2009-10-15 Herman Van Vlijmen Altered polypeptides, immunoconjugates thereof, and methods related thereto

Also Published As

Publication number Publication date
WO2017011773A2 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
WO2017011773A3 (en) Codon-optimized nucleic acids encoding antibodies
SA518400424B1 (en) Antibody molecules for cancer treatment
MX2021006615A (en) Trispecific binding proteins and methods of use.
AR106752A1 (en) PROTEINS OF UNION TO PD1 / CTLA4
MX2017014083A (en) Anti-cancer fusion polypeptide.
MX359953B (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein.
MX2018013784A (en) Gdf15 fusion proteins and uses thereof.
AU2015286820A8 (en) Stabilization of poly(A) sequence encoding DNA sequences
MX2018010824A (en) Inducible binding proteins and methods of use.
MX2017014716A (en) Anti-cancer fusion polypeptide.
WO2017015619A8 (en) Antibodies to coagulation factor xia and uses thereof
MX361728B (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen.
NZ705370A (en) Fcγriib-specific fc region variant
WO2016168755A8 (en) Method for mass humanization of non-human antibodies
EP4273160A3 (en) Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
AU2016277883A8 (en) PD-1-CD28 fusion proteins and their use in medicine
WO2008054561A3 (en) Proteins, nucleic acids encoding the same and associated methods of use
MX2018005392A (en) Engineered nucleic-acid targeting nucleic acids.
WO2014202616A3 (en) Rasamsonia gene and use thereof
WO2013151670A3 (en) Modified polynucleotides for the production of nuclear proteins
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
EA201591131A1 (en) DNA STRUCTURE ANTIBODY AND METHOD OF THEIR APPLICATION
WO2017218974A3 (en) Treatment of amd using aav2 variant with aflibercept
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2012069655A3 (en) Improved capping modules for designed ankyrin repeat proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16825265

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16825265

Country of ref document: EP

Kind code of ref document: A2